Frontier Wealth Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Frontier Wealth Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$40K	Hold	13,099	–	–	﹤0.01%	384
2022 Q1	$87K	Hold	13,099	–	–	﹤0.01%	391
2021 Q4	$109K	Hold	13,099	–	–	0.01%	412
2021 Q3	$97K	Hold	13,099	–	–	0.01%	411
2021 Q2	$89K	Hold	13,099	–	–	0.01%	419
2021 Q1	$135K	Sell	13,099 -14,000	-52%	-$153K	0.01%	371
2020 Q4	$190K	Hold	27,099	–	–	0.02%	360
2020 Q3	$221K	Hold	27,099	–	–	0.02%	326
2020 Q2	$187K	Hold	27,099	–	–	0.02%	332
2020 Q1	$129K	Hold	27,099	–	–	0.02%	271
2019 Q4	$237K	Hold	27,099	–	–	0.04%	261
2019 Q3	$90K	Hold	27,099	–	–	0.01%	296
2019 Q2	$134K	Hold	27,099	–	–	0.02%	290
2019 Q1	$168K	Hold	27,099	–	–	0.02%	343
2018 Q4	$91K	Hold	27,099	–	–	0.01%	346
2018 Q3	$176K	Hold	27,099	–	–	0.02%	366
2018 Q2	$208K	Hold	27,099	–	–	0.03%	354
2018 Q1	$606K	Buy	+27,099	New	+$601K	0.08%	201

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Frontier Wealth Management's JNCE Position: Q2 2022 in Review

Frontier Wealth Management held its Jounce Therapeutics, Inc. Common Stock (JNCE) position steady in Q2 2022 at 13,099 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #384.

Frontier Wealth Management first reported a position in JNCE in Q1 2018 and has held it in 18 quarters since. The position peaked at $606K in Q1 2018. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

Frontier Wealth Management held 13,099 shares of Jounce Therapeutics, Inc. Common Stock worth $40K as of Q2 2022.
Frontier Wealth Management left its Jounce Therapeutics, Inc. Common Stock share count unchanged in Q2 2022.
Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of Frontier Wealth Management's portfolio in Q2 2022, its #384 holding.
Frontier Wealth Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and has held it in 18 quarters since.
Frontier Wealth Management's Jounce Therapeutics, Inc. Common Stock position peaked at $606K in Q1 2018.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Frontier Wealth Management's 13F filing for Q2 2022, filed 12 Aug 2022.